載入中
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
收盤時
US$7.17
−US$0.20 · -2.71%
盤後
US$7.267
+US$0.097 · +1.35%
10月13日 下午4:46 ET
盤中時間採用ET。市場資料可能有所延遲。
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
日內區間
目前US$7.17
52週區間
目前US$7.17
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
90
深度低估
情緒
59
多空交錯
風險
43
風險偏高
動能
32
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
日內區間
目前US$7.17
52週區間
目前US$7.17
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 72.27億 EUR | 72.12億 EUR | 65.92億 EUR | 60.64億 EUR | 49.33億 EUR |
| 銷貨成本 | 46.47億 EUR | 44.18億 EUR | 41.08億 EUR | 38.5億 EUR | 29.71億 EUR |
| 毛利 | 25.8億 EUR | 27.95億 EUR | 24.83億 EUR | 22.14億 EUR | 19.63億 EUR |
| 研究與開發 | 3.58億 EUR | 3.84億 EUR | 3.95億 EUR | 3.61億 EUR | 3.55億 EUR |
| 銷售、一般及管理費用 | 10.21億 EUR | 11.44億 EUR | 12.66億 EUR | 11.08億 EUR | 10.62億 EUR |
| 營業費用 | 13.93億 EUR | 16.03億 EUR | 17.01億 EUR | 14.31億 EUR | 13.68億 EUR |
| 利息收入 | 3265.81萬 EUR | 4805.2萬 EUR | 6243萬 EUR | 3385.9萬 EUR | 1155.1萬 EUR |
| 利息支出 | 6億 EUR | 7.73億 EUR | 5.16億 EUR | 4.45億 EUR | 2.34億 EUR |
| 折舊和攤銷 | 4.32億 EUR | 4.38億 EUR | 4.46億 EUR | 4.11億 EUR | 3.6億 EUR |
| 營業利益 | 11.87億 EUR | 11.92億 EUR | 7.82億 EUR | 7.82億 EUR | 5.95億 EUR |
| 淨利 | 3.86億 EUR | 1.57億 EUR | 4231.8萬 EUR | 1.85億 EUR | 1.89億 EUR |
公司資料更新於 2026年10月14日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
年度分割調整後的每股現金分配。
US$0.302
2019年（完整年度）+6.0% 自從 2017
2026年（部分年度）：US$0.1058
US$0.285
2,017
US$0.3673
2,018
US$0.302
2,019
US$0.1058
2,026*
* 在現有股息歷史記錄中，該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月2日 | US$0.1058Annual | 2026年7月2日 | 2026年7月9日 |
股息 | 2025年8月12日 | US$0.1758Irregular | 2025年8月12日 | 2025年8月20日 |
股息 | 2021年6月3日 | US$0.3598Special | 2021年6月4日 | 2021年6月14日 |
股息 | 2020年10月30日 | US$0.1432Special | 2020年11月2日 | 2020年11月9日 |
股息 | 2019年12月2日 | US$0.1697Semi-Annual | 2019年12月3日 | 2019年12月11日 |
股息 | 2019年6月7日 | US$0.1323Special | 2019年6月10日 | 2019年6月18日 |
除息 2026年7月2日
US$0.1058
Annual
2026年7月2日登記 · 支付日 2026年7月9日
除息 2025年8月12日
US$0.1758
Irregular
2025年8月12日登記 · 支付日 2025年8月20日
除息 2021年6月3日
US$0.3598
Special
2021年6月4日登記 · 支付日 2021年6月14日
除息 2020年10月30日
US$0.1432
Special
2020年11月2日登記 · 支付日 2020年11月9日
除息 2019年12月2日
US$0.1697
Semi-Annual
2019年12月3日登記 · 支付日 2019年12月11日
除息 2019年6月7日
US$0.1323
Special
2019年6月10日登記 · 支付日 2019年6月18日
報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB1334.27萬0.12%107.38億 USD0.44%US$200.02-2.08%
Brandes International ETFBINV678.88萬1.28%5.3億 USD0.70%US$43.7186+0.71%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP260.68萬0.10%26.34億 USD0.20%US$65.01-0.38%
Brandes U.S. Small-Mid Cap Value ETFBSMC253.56萬1.51%1.68億 USD0.70%US$38.52+0.55%
State Street SPDR Portfolio Developed World ex-US ETFSPDW227.85萬0.01%406.96億 USD0.03%US$49.78+0.19%
Capital Group International Core Equity ETFCGIC88.97萬0.03%25.62億 USD0.54%US$35.58+0.20%
ActivePassive International Equity ETFAPIE20.83萬0.02%11.36億 USD0.45%US$38.63+0.60%
Invesco NASDAQ Future Gen 200 ETFQQQS11.59萬0.51%2275.83萬 USD0.20%US$40.5723-2.03%iShares Biotechnology ETFIBBBrandes International ETFBINVState Street SPDR S&P Kensho New Economies Composite ETFKOMPBrandes U.S. Small-Mid Cap Value ETFBSMCState Street SPDR Portfolio Developed World ex-US ETFSPDWCapital Group International Core Equity ETFCGICActivePassive International Equity ETFAPIEInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
